Severe acute respiratory syndrome coronavirus (SARS-CoV) main protease (M
pro), a protein required forthe maturation of SARS-CoV, is vital for its life cycle, making it an attractive target for structure-baseddrug design of anti-SARS drugs. The structure-based virtual screening of a chemical database containing58 855 compounds followed by the testing of potential compounds for SARS-CoV M
pro inhibition leads totwo hit compounds. The core structures of these two hits, defined by the docking study, are used for furtheranalogue search. Twenty-one analogues derived from these two hits exhibited IC
50 values below 50
![](/images/entities/mgr.gif)
M,with the most potent one showing 0.3
![](/images/entities/mgr.gif)
M. Furthermore, the complex structures of two potent inhibitorswith SARS-CoV M
pro were solved by X-ray crystallography. They bind to the protein in a distinct mannercompared to all published SARS-CoV M
pro complex structures. They inhibit SARS-CoV M
pro activity viaintensive H-bond network and hydrophobic interactions, without the formation of a covalent bond.Interestingly, the most potent inhibitor induces protein conformational changes, and the inhibition mechanisms,particularly the disruption of catalytic dyad (
His41 and Cys145), are elaborated.